Alternative splicing in the NF-κB signaling pathway

被引:63
作者
Leeman, Joshua R. [1 ]
Gilmore, Thomas D. [1 ]
机构
[1] Boston Univ, Dept Biol, Boston, MA 02215 USA
关键词
NF-kappaB; Splicing; Signal transcluction; mRNA; Tumor necrosis factor receptor; Toll-like receptors;
D O I
10.1016/j.gene.2008.07.015
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Activation of transcription factor NF-kappa B can affect the expression of several hundred genes, many of which are involved in inflammation and immunity. The proper NF-kappa B transcriptional response is primarily regulated by post-translational modification of NF-kappa B signaling constituents. Herein, we review the accumulating evidence suggesting that alternative splicing of NF-kappa B signaling components is another means of controlling NF-kappa B signaling. Several alternative splicing events in both the tumor necrosis factor and Toll/interleukin-1 NF-kappa B signaling pathways can inhibit the NF-kappa B response, whereas others enhance NF-kappa B signaling. Alternative splicing of mRNAs encoding some NF-kappa B signaling components can be induced by prolonged exposure to an NF-kappa B-activating signal, such as lipopolysaccharide, suggesting a mechanism for negative feedback to dampen excessive NF-kappa B signaling. Moreover, some NF-kappa B alternative splicing events appear to be specific for certain diseases, and could serve as therapeutic targets or biomarkers. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:97 / 107
页数:11
相关论文
共 108 条
[1]   Biological role of interleukin 1 receptor antagonist isoforms [J].
Arend, WP ;
Guthridge, CJ .
ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 :60-64
[2]   The balance between IL-1 and IL-1Ra in disease [J].
Arend, WR .
CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (4-5) :323-340
[3]   EMBRYONIC LETHALITY AND LIVER DEGENERATION IN MICE LACKING THE RELA COMPONENT OF NF-KAPPA-B [J].
BEG, AA ;
SHA, WC ;
BRONSON, RT ;
GHOSH, S ;
BALTIMORE, D .
NATURE, 1995, 376 (6536) :167-170
[4]  
BEG AA, 1996, SCIENCE, V274, P784
[5]   Identification of the familial cylindromatosis tumour-suppressor gene [J].
Bignell, GR ;
Warren, W ;
Seal, S ;
Takahashi, M ;
Rapley, E ;
Barfoot, R ;
Green, H ;
Brown, C ;
Biggs, PJ ;
Lakhani, SR ;
Jones, C ;
Hansen, J ;
Blair, E ;
Hofmann, B ;
Siebert, R ;
Turner, G ;
Evans, DG ;
Schrander-Stumpel, C ;
Beemer, FA ;
van den Ouweland, A ;
Halley, D ;
Delpech, B ;
Cleveland, MG ;
Leigh, I ;
Leisti, J ;
Rasmussen, S ;
Wallace, MR ;
Fenske, C ;
Banerjee, P ;
Oiso, N ;
Chaggar, R ;
Merrett, S ;
Leonard, N ;
Huber, M ;
Hohl, D ;
Chapman, P ;
Burn, J ;
Swift, S ;
Smith, A ;
Ashworth, A ;
Stratton, MR .
NATURE GENETICS, 2000, 25 (02) :160-165
[6]   TNF-mediated inflammatory disease [J].
Bradley, J. R. .
JOURNAL OF PATHOLOGY, 2008, 214 (02) :149-160
[7]   EST comparison indicates 38% of human mRNAs contain possible alternative splice forms [J].
Brett, D ;
Hanke, J ;
Lehmann, G ;
Haase, S ;
Delbrück, S ;
Krueger, S ;
Reich, J ;
Bork, P .
FEBS LETTERS, 2000, 474 (01) :83-86
[8]   Tumor necrosis factor receptor (TNFR)-associated factor 2A (TRAF2A), a TRAF2 splice variant with an extended RING finger domain that inhibits TNFR2-mediated NF-κB activation [J].
Brink, R ;
Lodish, HF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (07) :4129-4134
[9]   Splice variants as cancer biomarkers [J].
Brinkman, BMN .
CLINICAL BIOCHEMISTRY, 2004, 37 (07) :584-594
[10]  
BROWNELL E, 1989, ONCOGENE, V4, P935